ArticleEntropy (Basel, Switzerland)2022
Cost-Sensitive KNN Algorithm for Cancer Prediction Based on Entropy Analysis.
Article in Entropy (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 22 citations in OpenAlex.
- Predicting esophageal cancer response to neoadjuvant therapy with magnetic resonance imaging radiomics.World journal of gastrointestinal oncology · 2025Article
- Unlocking artificial intelligence, machine learning and deep learning to combat therapeutic resistance in metastatic castration-resistant prostate cancer: a comprehensive review.Ecancermedicalscience · 2025Review
- A reinforcement learning model for AI-based decision support in skin cancer.Nature medicine · 2023Article
- Mass Spectrometry-Based Proteomics Workflows in Cancer Research: The Relevance of Choosing the Right Steps.Cancers · 2023Review
- The Application of Artificial Intelligence to Cancer Research: A Comprehensive Guide.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Early diagnosis of cancer is beneficial in the formulation of the best treatment plan; it can improve the survival rate and the quality of patient life. However, imaging detection and needle biopsy usually used not only find it difficult to effectively diagnose tumors at early stage, but also do great harm to the human body. Since the changes in a patient's health status will cause changes in blood protein indexes, if cancer can be diagnosed by the changes in blood indexes in the early stage of cancer, it can not only conveniently track and detect the treatment process of cancer, but can also reduce the pain of patients and reduce the costs. In this paper, 39 serum protein markers were taken as research objects. The difference of the entropies of serum protein marker sequences in different types of patients was analyzed, and based on this, a cost-sensitive analysis model was established for the purpose of improving the accuracy of cancer recognition. The results showed that there were significant differences in entropy of different cancer patients, and the complexity of serum protein markers in normal people was higher than that in cancer patients. Although the dataset was rather imbalanced, containing 897 instances, including 799 normal instances, 44 liver cancer instances, and 54 ovarian cancer instances, the accuracy of our model still reached 95.21%. Other evaluation indicators were also stable and satisfactory; precision, recall, F1 and AUC reach 0.807, 0.833, 0.819 and 0.92, respectively. This study has certain theoretical and practical significance for cancer prediction and clinical application and can also provide a research basis for the intelligent medical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.